SCHEMBL6216656

SCHEMBL6216656

CC(C)(C)OC(=O)N1CCC=C(C(N)=O)C1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 2/20 0.47
ESR2 Q92731 1/20 0.45
GPR119 Q8TDV5 4/20 0.44
MAPK1 P28482 1/20 0.44
USP2 O75604 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ADORA1 P30542 1/20 0.41
MAPT P10636 2/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
PARP1 P09874 1/20 0.39
KDM4E B2RXH2 1/20 0.38
THRB P10828 1/20 0.38
PTPN2 P17706 1/20 0.38
PTPN1 P18031 1/20 0.38
PTPN6 P29350 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2270068 0.88 ESR2 (0.45) NR1H2ESR2GPR119MAPK1USP2
SCHEMBL3729307 0.85 CHRM3 (0.56) NR1H2ESR2GPR119MAPK1USP2
SCHEMBL20314993 0.84 ESR2 (0.42) NR1H2ESR2GPR119MAPK1USP2
SCHEMBL6218755 0.81 ADORA1 (0.49) NR1H2ESR2GPR119MAPK1SMN1; SMN2
SCHEMBL12519920 0.81 ESR2 (0.47) NR1H2ESR2GPR119MAPK1USP2
SCHEMBL18556946 0.81 ESR2 (0.50) NR1H2ESR2GPR119MAPK1USP2
SCHEMBL25043924 0.80 GPR119 (0.45) NR1H2ESR2GPR119MAPK1USP2
SCHEMBL22124338 0.80 LMNA (0.51) NR1H2ESR2GPR119MAPK1USP2
SCHEMBL14972445 0.80 NR1H2 (0.43) NR1H2ESR2GPR119MAPK1USP2
SCHEMBL30262739 0.79 ESR2 (0.46) NR1H2ESR2GPR119MAPK1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025130765-A1 COMPOUNDS, COMPOSITIONS AND METHODS THEREOF HEPAITECH (BEIJING) BIOPHARMA TECHNOLOGY CO., LTD. (CN) 2025-06-26 WO disclosed
EP-1176146-B1 CARBAMOYL TETRAHYDROPYRIDINE DERIVATIVES TAISHO PHARMACEUTICAL CO LTD (JP) 2005-06-08 EP disclosed
US-6894168-B2 Carbamoyl tetrahydropyridine derivatives TAISHO PHARMACEUTICAL CO., LTD. (JP) 2005-05-17 US disclosed
EP-1449843-A1 Intermediates for the preparation of carbamoyl tetrahydropyridine derivatives Taisho Pharmaceutical Co. Ltd. (JP) 2004-08-25 EP disclosed
US-20030191122-A1 Carbamoyl tetrahydropyridine derivatives NAKAZATO ATSURO (JP) 2003-10-09 US disclosed
US-6600038-B1 Intermediates for the preparation thereof are provided. The derivatives described above are effective for diseases which are believed to involve CRF. involving Corticotropin Releasing Factor (CRF), such as depression, anxiety, TAISHO PHARMACEUTICAL CO., LTD. (JP) 2003-07-29 US disclosed
EP-1176146-A1 CARBAMOYL TETRAHYDROPYRIDINE DERIVATIVES TAISHO PHARMACEUTICAL CO., LTD (JP) 2002-01-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191122-A1 Carbamoyl tetrahydropyridine derivatives CNR1, CRHR1, CRH NR1H2 383/4885ESR2 1696/4885GPR119 332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.